Stephen V Liu: The optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center, posted on X/Twitter:

“What is the optimal strategy for unresectable stage III NSCLC after chemoradiation in EGFR mutant NSCLC? Retrospective look JTO and JTO CRR (n=136) shows 2y rwPFS rate 86% with osimertinib, 30% with durvalumab, 27% with observation. Await prospective data from the phase III LAURA trial.

Point against immunotherapy: In 45 patients who progressed after consolidation durvalumab (PACIFIC), 37 then received EGFR TKI therapy. In those patients, 38% develped trAEs including 14% pneumonitis and 14% diarrhea.”

Read further.
Source: Stephen V Liu/X